Article Sidebar
Published:
Jun 22, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Evaluation of L-carnitine in an animal model of cholesterol induced atherosclerosis
Abstract
Purpose: To explore the effect of L-carnitine on atherosclerotic plaques in hyperlipidemic rabbits.
Methods: Twenty five male white New Zealand rabbits were randomized into five groups (n = 5): In the normal control (NC) group, the animals were fed on a plain chow diet for 75 days. In atherosclerosis (AS) group, the animals were fed on a hypercholesterolemic diet for 75 days. In atorvastatin (ATOR) group, the animals were fed on a hypercholesterolemic diet for 75 days and received atorvastatin via oral gavage (20 mg/kg/day) from day 45 for 30 days. In L-carnitine (L) group, the animals were fed on a hypercholesterolemic diet for 75 days and received intraperitoneal L-carnitine (250 mg/kg/day) from day 45 for 30 days (end of the study). In ATOR/L group, the animals were fed on a hypercholesterolemic diet for 75 days, and received both atorvastatin and L-carnitine with the aforementioned dosage from day 45 for 30 days. Triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL) and lowdensity lipoprotein (LDL-C) in sera were determined. The aorta, including the ascending and descending parts, was excised to measure plague size (end of the study). The blood samples were taken from a marginal ear vein.
Results: Rabbits in AS group showed highly significant increase in serum total cholesterol and LDL-C levels compared to NC group (p < 0.05). Daily administration of L-carnitine significantly reduced serum levels of total cholesterol and LDL-C compared to AS (positive control) group (p < 0.05). Additionally, no significant difference was found between serum levels of total cholesterol and LDL-C in groups that received either atorvastatin or L-carnitine (p > 0.05). Combined administration of L-carnitine and atorvastatin produced no benefits over either of them alone (p > 0.05).
Conclusion: The results indicate that the administration of L-carnitine has anti-atherosclerotic effects by reducing oxidized LDL cholesterol levels but further investigations are recommended to ascertain these findings.
